Functional Connectivity Parkinson Disease
- Conditions
- Parkinson Disease
- Registration Number
- NCT01798563
- Lead Sponsor
- University of Colorado, Denver
- Brief Summary
In this study the investigators are looking at two subtypes of Parkinson Disease (PD); "tremor-dominant" (TD) and postural imbalance and gait disorder (PIGD). This study will use magnet resonance imaging (MRI) to see how the brain reacts while resting and doing a finger-tapping task while on and off PD medication. This study will look at the differences between the two sub-types of PD and healthy volunteers.
The investigators will test the hypothesis that connectivity at rest within the motor cortex and between the motor cortex and motor-associated regions such as the supplementary motor area and the pre motor cortex will not be as strong in PIGD compared to TD (increased activity and functional connectivity in TD group)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 86
- English as their primary language
- Patients with Parkinson disease and healthy controls will be enrolled
- Parkinson patients must be on a dopaminergic medication (levodopa or dopamine agonist) and on a stable dose over the prior month
- If unable to provide informed consent
- Pregnancy
- Excess of 300lbs
- Claustrophobia
- Metal in body
- Untreated neurological or psychiatric condition, who are delusional or have hallucinations, with cognitive impairment (MOCA<26), with a history of head injury sufficient to cause a concussion, or with significant systemic medical diseases (e.g. heart failure, liver failure, kidney failure, poorly controlled diabetes, etc.)
- Healthy control subjects will be excluded if taking any type of dopaminergic or anti-dopaminergic medication
- Subjects who are unable to demonstrate understanding of the study procedures and risks will be excluded
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Second level contrast between Parkinson Disease (PD) and Healthy Controls (HC). At time of MRI scan: 12 or more hours after their last dose of dopaminergic medication. Differences in connectivity as measured by correlation coefficients between nodes of the motor network at rest and during a tapping motor task in PD patients of two motor subtypes and matched healthy controls.
Correlation coefficients between nodes of the motor network at rest and during a tapping motor task. At time of 2nd MRI scan: 1 to 3 hours after taking their usual dose(s) dopaminergic medication(s). A measure of the correlation coefficients between nodes of the motor network at rest and during a tapping motor task between the "OFF" and "ON" dopaminergic medication states in the two motor subtype PD patients.
- Secondary Outcome Measures
Name Time Method Connectivity between other motor and non-motor brain regions during the tasks. At time of MRI scan,12 or more hours after their last dose of dopaminergic medication. Secondary outcome measures include measuring the connectivity between other motor and non-motor brain regions during the tasks.
Task-related whole-brain activations. At time of 2nd MRI scan, 1 to 3 hours after taking their usual dose(s) dopaminergic medication(s). Secondary outcome measures include task-related whole-brain activations as assessed by changes in blood oxygen-dependent (BOLD) contrast during functional magnetic resonance imaging (fMRI) scanning.
Correlations of brain activity and functional connectivity to structural connectivity measures and behavioral and clinical assessments At time of 2nd MRI scan. 1 to 3 hours after taking their usual dose(s) dopaminergic medication(s). Secondary outcome measures include a measure of the correlations of brain activity and functional connectivity to structural connectivity measures as well as behavioral and clinical assessments.
Trial Locations
- Locations (1)
University of Colorado Denver
🇺🇸Aurora, Colorado, United States